Quince Therapeutics price target raised to $5 from $4 at D. Boral Capital

D. Boral Capital expert Jason Kolbert raised the firm’s price target connected Quince Therapeutics (QNCX) to $5 from $4 and keeps a Buy standing connected the shares aft the institution said the past diligent has completed their past sojourn successful the pivotal Phase 3 NEAT objective proceedings evaluating encapsulated dexamethasone sodium phosphate successful patients with Ataxia-Telangiectasia. The steadfast cites the rolling of its valuation metrics retired a twelvemonth for the people bump.

Claim 50% Off TipRanks Premium and Invest with Confidence

• Unlock hedge-fund level information and almighty investing tools designed to assistance you marque smarter, sharper decisions

• Stay up of the marketplace with the latest quality and investigation truthful your portfolio is ever positioned for maximum potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected QNCX:

Disclaimer & DisclosureReport an Issue

• Quince Therapeutics announces past sojourn from past diligent successful NEAT trial

• Quince Therapeutics publishes summary of early-stage objective studies of eDSP

• Promising Outlook for Quince Therapeutics: Phase 3 Study and Innovative Platform Drive Buy Recommendation

• Quince Therapeutics Reports Q3 2025 Financial Results

• Quince Therapeutics reports Q3 EPS (25c), statement (22c)